Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial

Markus Béchir, Milo A Puhan, Mario Fasshauer, Reto A Schuepbach, Reto Stocker, Thomas A Neff, Markus Béchir, Milo A Puhan, Mario Fasshauer, Reto A Schuepbach, Reto Stocker, Thomas A Neff

Abstract

Introduction: There are limited data on the efficacy of early fluid resuscitation with third-generation hydroxyethyl starch (HES 130) in burn injury. Adverse effects of HES on survival and organ function have been reported.

Methods: In this randomized, controlled, double-blind trial, 48 patients with severe burn injury were assigned to receive either lactated Ringer's solution plus 6% HES 130/0.4 in a ratio of 2:1 or lactated Ringer's solution with no colloid supplement for the first 72 hours. Primary outcome parameter was the group difference of administered total fluid from intensive care unit (ICU) admission up to day 3. Secondary outcomes included kidney and lung injury and failure, length of stay, and mortality.

Results: Three-day totals of administered resuscitation fluid (medians) were 21,190 mL in the lactated Ringer's group and 19,535 mL in the HES group (HES: -1,213 mL; P = 0.39). Creatinine levels from day 1 to 3 (HES: +0.4 μmol/L; 95% confidence interval (CI) -18.7 to 19.5; P = 0.97) and urinary outputs from day 1 to 3 (HES: -58 mL; 95% CI -400 to 283; P = 0.90) were not different. Six patients in each group developed acute respiratory distress syndrome (ARDS) (risk ratio 0.96; 95% CI 0.35 to 2.64; P = 0.95). Length of ICU stay (HES vs. lactated Ringer's: 28 vs. 24 days; P = 0.80) and length of hospital stay (31 vs. 29 days; P = 0.57) were similar. Twenty-eight-day mortality was 4 patients in each group (risk ratio 0.96; 95% CI 0.27 to 4.45; P = 0.95), and in-hospital mortality was 8 in the HES group vs. 5 patients in the lactated Ringer's group (hazard ratio 1.86; 95% CI 0.56 to 6.19; P = 0.31).

Conclusions: There was no evidence that early fluid resuscitation with balanced HES 130/0.4 (6%) in addition to lactated Ringer's solution would lead to a volume-sparing effect in severe burn injury. Together with the findings that early renal function, incidence of ARDS, length of stay, and mortality were not negatively influenced by HES in this setting, balanced HES 130/0.4 (6%) plus lactated Ringer's solution could not be considered superior to lactated Ringer's solution alone.

Trial registration: ClinicalTrials.gov NCT01012648.

Figures

Figure 1
Figure 1
Hct, hematocrit; MAP, mean arterial pressure; ScvO2, central venous oxygen saturation; UO, urinary output.
Figure 2
Figure 2
Study flow diagram.

References

    1. Pitt RM, Parker JC, Jurkovich GJ, Taylor AE, Curreri PW. Analysis of altered capillary pressure and permeability after thermal injury. J Surg Res. 1987;17:693–702. doi: 10.1016/0022-4804(87)90013-8.
    1. Youn YK, LaLonde C, Demling R. The role of mediators in the response to thermal injury. World J Surg. 1992;17:30–36. doi: 10.1007/BF02067111.
    1. Warden GD. Burn shock resuscitation. World J Surg. 1992;17:16–23. doi: 10.1007/BF02067109.
    1. Yowler CJ, Fratianne RB. Current status of burn resuscitation. Clin Plast Surg. 2000;17:1–10.
    1. Cocks AJ, O’Connell A, Martin H. Crystalloids, colloids and kids: a review of paediatric burns in intensive care. Burns. 1998;17:717–724. doi: 10.1016/S0305-4179(98)00102-8.
    1. Holm C. Resuscitation in shock associated with burns. Tradition or evidence-based medicine? Resuscitation. 2000;17:157–164. doi: 10.1016/S0300-9572(00)00159-3.
    1. Baxter CR. Fluid volume and electrolyte changes of the early postburn period. Clin Plast Surg. 1974;17:693–703.
    1. Baxter CR, Marvin JA, Curreri PW. Early management of thermal burns. Postgrad Med. 1974;17:131–139.
    1. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ. 1998;17:235–240. doi: 10.1136/bmj.317.7153.235.
    1. Ennis JL, Chung KK, Renz EM, Barillo DJ, Albrecht MC, Jones JA, Blackbourne LH, Cancio LC, Eastridge BJ, Flaherty SF, Dorlac WC, Kelleher KS, Wade CE, Wolf SE, Jenkins DH, Holcomb JB. Joint Theater Trauma System implementation of burn resuscitation guidelines improves outcomes in severely burned military casualties. J Trauma. 2008;17:S146–S151. doi: 10.1097/TA.0b013e318160b44c. Discussion S151-142.
    1. Wharton SM, Khanna A. Current attitudes to burns resuscitation in the UK. Burns. 2001;17:183–184. doi: 10.1016/S0305-4179(00)00097-8.
    1. Bechir M, Puhan MA, Neff SB, Guggenheim M, Wedler V, Stover JF, Stocker R, Neff TA. Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury. Crit Care. 2010;17:R123. doi: 10.1186/cc9086.
    1. Vlachou E, Gosling P, Moiemen NS. Hydroxyethylstarch supplementation in burn resuscitation-a prospective randomised controlled trial. Burns. 2010;17:984–991. doi: 10.1016/j.burns.2010.04.001.
    1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;17:818–824. doi: 10.1164/ajrccm.149.3.7509706.
    1. Cancio LC, Chavez S, Alvarado-Ortega M, Barillo DJ, Walker SC, McManus AT, Goodwin CW. Predicting increased fluid requirements during the resuscitation of thermally injured patients. J Trauma. 2004;17:404–413. doi: 10.1097/01.TA.0000075341.43956.E4. discussion 413–404.
    1. Cartotto RC, Innes M, Musgrave MA, Gomez M, Cooper AB. How well does the Parkland formula estimate actual fluid resuscitation volumes? J Burn Care Rehabil. 2002;17:258–265. doi: 10.1097/00004630-200207000-00006.
    1. Friedrich JB, Sullivan SR, Engrav LH, Round KA, Blayney CB, Carrougher GJ, Heimbach DM, Honari S, Klein MB, Gibran NS. Is supra-Baxter resuscitation in burn patients a new phenomenon? Burns. 2004;17:464–466. doi: 10.1016/j.burns.2004.01.021.
    1. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg. 2002;17:544–551. Table of contents.
    1. Thompson WL, Fukushima T, Rutherford RB, Walton RP. Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch. Surg Gynecol Obstet. 1970;17:965–972.
    1. De Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch administration in a surgical patient. Am J Med. 2001;17:417–418. doi: 10.1016/S0002-9343(01)00873-7.
    1. Waldhausen P, Kiesewetter H, Leipnitz G, Scielny J, Jung F, Bambauer R, von Blohn G. Hydroxyethyl starch-induced transient renal failure in preexisting glomerular damage. Acta Med Austriaca. 1991;17:52–55.
    1. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma) Br J Anaesth. 2011;17:693–702. doi: 10.1093/bja/aer229.
    1. Boussekey N, Darmon R, Langlois J, Alfandari S, Devos P, Meybeck A, Chiche A, Georges H, Leroy O. Resuscitation with low volume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kidney injury. Crit Care. 2010;17:R40. doi: 10.1186/cc8920.
    1. Dubin A, Pozo MO, Casabella CA, Murias G, Palizas F Jr, Moseinco MC, Kanoore Edul VS, Palizas F, Estenssoro E, Ince C. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. J Crit Care. 2010;17:659. e651–658.
    1. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J. 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;17:124–134. doi: 10.1056/NEJMoa1204242.
    1. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA. CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;17:1901–1911. doi: 10.1056/NEJMoa1209759.
    1. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011;17:635–645. doi: 10.1213/ANE.0b013e31820ad607.
    1. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA. 2013;17:678–688. doi: 10.1001/jama.2013.430.
    1. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013;17 CD000567.
    1. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med. 2013;17:558–568. doi: 10.1007/s00134-013-2840-0.
    1. Haase N. Systematic review not influenced by Boldt’s work. BMJ. 2013;17:f2280. doi: 10.1136/bmj.f2280.
    1. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38–0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ. 2013;17:f839. doi: 10.1136/bmj.f839.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere